The study, which will be published in the February issue (Volume 14 Issue 2) of the journal Structure, was led by Ian A. Wilson, D.Phil., of Scripps Research Department of Molecular Biology and The Skaggs Institute for Chemical Biology, and Kim D. Janda, Ph.D., of Scripps Research Departments of Chemistry and Immunology and The Skaggs Institute for Chemical Biology.
Despite intensive research, cocaine abuse continues to be a major public health problem, so far eluding efforts at developing an effective therapeutic agent to counter the craving, addiction, and overdose of the drug. To date, no treatment has been approved by the Food and Drug Administration (FDA).
Commenting on the new findings, Xueyong Zhu, Ph.D., the primary author of the study and a staff scientist in the Wilson laboratory said, "Development of effective therapies for cocaine abuse has been a long-standing goal, and a number of medications under study do show some promise. Immunopharmacotherapy has been proposed as a way to neutralize the drug outside the central nervous system- basically soaking up the drug before it has a chance to cross the blood brain barrier-as a potentially effective new approach to treat cocaine abuse."
Using a monoclonal antibody endowed not only with high binding ability, but also with sufficient catalytic activity to metabolize cocaine, would have potentially enhanced therapeutic effects, Zhu said. This antibody could intercept cocaine in the blood stream before it reaches the central nervous system-stopping the drug cold. Because cocaine has a half life of approximately 30 minutes inside the human body, a cocaine catalytic antibody would basically have to out-run the body's natural metabolism process to have any serious impact on the psychoactive effects of the drug.
Generated by x-ray crystallography, pictures of the conformational changes that occur during the antibody's complete catalytic cycle show the molecular basis for catalysis and reveal possible mutations that could increase catalytic proficiency. This, Zhu pointed out, provides a foundation for the humanization and mutagenesis of the antibody to enhance its cocaine-hydrolyzing activity and make future human clinical trials feasible. "Given the fact that catalytic antibodies have been produced with the same levels of efficiency as natural enzymes, it seems well within the realm of possibility," he added.
To reach this ambitious goal, however, it may be necessary to explore new incremental approaches for optimizing the efficiency of such catalytic activity. Novel functional groups could be introduced into first generation antibody catalysts by multiple rounds of mutagenesis and selection to produce improvements. In essence, this would allow scientists to dramatically accelerate the evolutionary process, producing improvements in the immune system in weeks or months that previously took billions of years.
"The structural insights into antibody catalysis that we have shown with 7A1 Fab' are critical for any future improvement of effective biocatalysts," Zhu said. "One of the main goals of our lab has been to focus on catalytic antibodies that will have a direct impact on public health issues. With the snapshots of the complete cycle of the cocaine antibody catalytic reaction, we have shed new light on the sequence of events in an antibody-mediated reaction and provided a rare glimpse of the structural dynamics involved. With this information, it's possible to move onto the next step in the development of a treatment for cocaine abuse and addiction."
Other authors of the study include Tobin J. Dickerson, Claude J. Rogers, Gunnar F. Kaufmann, Jenny M. Mee, and Kathleen M. McKenzie.
Support for the study was provided by grants from the National Institutes of Health, The Skaggs Institute for Chemical Biology and Scripps Research.
About The Scripps Research Institute
The Scripps Research Institute, headquartered in La Jolla, California, in 18 buildings on 40 acres overlooking the Pacific Ocean, is one of the world's largest independent, non-profit biomedical research organizations. It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel.
Scripps Florida, a 364,000 square-foot, state-of-the-art biomedical research facility, will be built in Palm Beach County. The facility will focus on basic biomedical science, drug discovery, and technology development. Palm Beach County and the State of Florida have provided start-up economic packages for development, building, staffing, and equipping the campus. Scripps Florida now operates with approximately 160 scientists, technicians, and administrative staff at 40,000 square-foot lab facilities on the Florida Atlantic University campus in Jupiter.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.